Millers Capital
SINGAPORE, SINGAPORE / ACCESSWIRE / June 3, 2024 / The IPO market has roared back to life in 2024, showcasing its strongest start since the 2021 boom. High-profile transactions involving companies like Galderma, Douglas, Puig, and CVC have signaled a resurgence, setting the stage for a robust year ahead.
Our analysis for the first quarter of this year highlights a notable recovery in Europe's IPO scene, with nearly €5 billion raised in the first quarter alone, according to S&P Global Market Intelligence. Private equity (PE)-backed IPOs have been particularly influential, accounting for three of the top five listings. This trend, along with a healthy pipeline, suggests a sustained recovery through the year. While consumer and luxury sectors have been prominent, the overall pipeline remains diverse. Let's explore the factors behind this recovery and what the rest of 2024 might hold.
Drivers of Europe's IPO Resurgence
The past few years have been tumultuous, with economic shocks post-pandemic, including geopolitical tensions and rising energy prices, leading to inflation and synchronized interest rate hikes by central banks. These factors created an uncertain market environment, widening the gap between investor and issuer expectations.
By late 2023, however, optimism returned as macroeconomic conditions stabilized. Declining energy costs, a rebound in global manufacturing, and inflation trends nearing the European Central Bank's 2% target have bolstered economic confidence. These developments have driven strong equity market performance, with the STOXX Europe 600 reaching record highs. Additionally, the volatility index has remained stable, supporting secondary equity markets.
These positive changes have rekindled investor confidence, paving the way for a functioning IPO market. This renewed confidence, coupled with a backlog of exit demand, has created an ideal environment for issuers and sellers.
Private Equity's Role in IPO Market Dynamics
Since 2021, macroeconomic challenges and rising interest rates have reshaped the PE exit landscape. IPOs had taken a backseat as PE firms held onto investments to avoid lower valuations, creating a backlog of maturing investments. PitchBook data indicates that global PE assets under management now exceed $5 trillion, highlighting substantial unrealized value.
The recent stabilization of equity markets has opened a window for more PE-backed IPOs. As pressure to realize value mounts, we anticipate increased activity in the IPO market for PE-backed assets. The overhang from 2021's PE-backed IPOs will likely drive follow-on equity issuance in 2024 and beyond.
As Thomas Gallagher, Director of Private Equity at Millers Capital Investment Pte Ltd., stated, "The resurgence of the IPO market provides an excellent opportunity for PE firms to unlock value in their portfolios, which had been on hold due to market volatility."
Global IPO Trends and Regional Variations
Globally, while Western IPO markets have reopened, IPO values in Q1 2024 were down 6% compared to Q1 2023, primarily due to a 48% drop in the Asia-Pacific region. Nonetheless, India's stock market continues to thrive, with $2 billion in IPOs in Q1 2024. The Middle East has also shifted focus from oil and gas to other industries, signaling a maturing market with broader appeal to international investors.
The performance of IPO markets in Europe and the U.S. is heavily influenced by global macroeconomic conditions, while regions like the Middle East and India are driven by local factors such as domestic growth.
Looking Ahead: The Future of IPOs in 2024 and Beyond
Optimism abounds for Western IPO markets through 2024 and into 2025, supported by a strong pipeline, robust market performance, lower volatility, and an improved inflation outlook. Successful IPOs in Q1 have set a positive tone, with a diverse range of issuers expected to support a vibrant IPO window in the latter half of the year.
However, geopolitical uncertainties and upcoming elections could temper this optimism. Innovation in IPO structuring, such as fixed-price offerings and smaller free floats, alongside alternative funding mechanisms like convertible instruments, will likely continue to evolve.
The London IPO market also stands at a pivotal point, with significant changes to the UK listing regime aimed at increasing its attractiveness. Interest from domestic and international companies suggests a favorable outlook for London listings.
Strategic Preparation: Key to IPO Success
For potential issuers, readiness is crucial to capitalize on the IPO window. The process, from strategic planning and readiness assessments to transaction execution and pricing, can take up to 24 months. Companies are focusing on improving their reporting environments, controls, and ESG disclosures to be "fit for listing."
With ample investable cash available, quality and stock fundamentals are paramount for IPO investors. Unlike the earlier boom driven by pre-revenue tech companies, current listings must demonstrate solid profitability. Planning for optionality, such as dual-track processes, can create tension in price discovery and align expectations with historical valuation levels.
Conclusion
The European IPO market is clearly on the mend, with a strong start to 2024 and positive aftermarket performance. As we approach the second half of the year, the market is expected to continue its recovery, contingent on the persistence of favorable conditions.
Contact:
Millers Capital Investment Pte Ltd.
Website: www.millers-capital.com
Media Relations: media@millers-capital.com
Singapore Office
21 Bukit Batok Cres.
25-78 Wcega Tower
Email: info@millers-capital.com
Phone: +65 3159 2522
Luxembourg Office
65 Avenue De La Gare 1611
Phone: +352 2843 1117
SOURCE: Millers Capital
View the original press release on accesswire.com
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Datavault AI Announces Target to Expand its AI Driven Data Monetization Network to Over 100 Cities Across the Contiguous United States, Starting in the Second Half of 2026 with Corresponding 2027 Revenue Target12.1.2026 14:05:00 CET | Press release
Datavault AI expects to have a fully operational network with over 100 nodes across 33 cities nationwide, generating revenue in the second half of 2026. Target revenue for this project is $400 to $500 million, thereby supporting the $200 million revenue guidance for 2026. With the full deployment of Datavault AI's nodes across 100+ cities throughout the United States, the 2027 revenue target is $2.0 to $3.0 billion for 2027. New York and Philadelphia edge network activation positions Datavault AI to potentially capture a significant share of the insurance and financial sectors, the healthcare industry, and enterprise opportunities. PHILADELPHIA, PENNSYLVANIA / ACCESS Newswire / January 12, 2026 / Datavault AI Inc. (Nasdaq:DVLT), a leader in AI-driven data valuation, monetization, credentialing, and digital engagement technologies, today highlighted the strategic importance of its New York and Philadelphia edge network deployment with Available Infrastructure's SanQtum AI platform. This
OBI Pharma and TegMine Therapeutics Sign Exclusive Global License Agreement for Glycan-Targeting ADC12.1.2026 13:00:00 CET | Press release
Successful Delivery of Commissioned ADC Candidate to Advance the Collaboration Between OBI and TegMine TAIPEI, TW / ACCESS Newswire / January 12, 2026 / OBI Pharma (4174.TWO) announced that it has entered into a commercial license agreement with TegMine Therapeutics, Inc. (TegMine), a San Francisco-based biopharma focused on developing antibodies targeting cancer-associated glycans and glycoproteins, for a glycan-targeting ADC. Under the terms of the agreement, OBI is eligible to receive an upfront payment as well as development and commercial milestones. Following product launch, OBI will also receive royalties based on a tiered percentage of annual net sales. While the detailed financial terms are not disclosed in accordance with the confidentiality provisions, the overall deal economics are broadly comparable to those of recent similar licensing transactions in the market. TegMine will obtain the exclusive global rights to develop and commercialize the ADC under the license agreemen
Charlie's Holdings (OTCQB:CHUC) Signs Agreement with IKE Tech to Commercialize Transformational Age-Gated Vapes that Will Address FDA Concerns Related to Youth Access12.1.2026 12:00:00 CET | Press release
SBX Product Line Will Feature First-Ever AI-Powered Blockchain-Based Age-Gating System for Vape Products IKE's patented biometric BLE Bluetooth chip and blockchain-based app will enable Charlie's to ensure that underage individuals will not be able to activate or utilize the Company's age-gated products. The IKE Licensing Agreement provides CHUC with a first mover advantage in youth access prevention (one of the FDA's top priorities) and a three-year exclusivity period for age-gated nicotine analogue products. Charlie's will test market the IKE age-gating system this spring with the Company's popular SBX nicotine analogue product line; simultaneously, Charlie's intends to incorporate the revolutionary technology into its PACHA branded Electronic Nicotine Delivery Systems (ENDS). COSTA MESA, CA / ACCESS Newswire / January 12, 2026 / Charlie's Holdings, Inc. (OTCQB:CHUC) ("Charlie's" or the "Company"), an industry leader in the premium vapor products space, today reported that the Compan
Datavault AI Celebrates Successful Completion of Dream Bowl XIV, Pioneering Blockchain Innovation in Sports Entertainment12.1.2026 12:00:00 CET | Press release
On January 10, 2026, a few dozen of NFL Alumni Greats (click here for a list of participating athletes) live-autographed 100 Footballs (click here to view the autographed NFL Alumni Footballs) and 500 Jerseys (click here to view the autographed NFL Alumni Jerseys); Starting on February 1, 2026, these special, one-time, live-autographed memorabilia items are to be given away by lottery to eligible holders of Dream Bowl Meme Coin I tokens and, following their distribution date (currently set for February 21, 2026), Dream Bowl Meme Coin II tokens and will be tradable on the upcoming International NIL Exchange; $25,000 E-Sports Scholarships Raised by Sponsors were Given to Dream Bowl Madden and Team E-Sports Champions; and 70 Student Star Athletes Showcased their Talent to USFL, NFL and European League Scouts (click here to view the Special Dream Bowl XIV Participants' Jerseys). PHILADELPHIA, PENNSYLVANIA / ACCESS Newswire / January 12, 2026 / Datavault AI Inc. (NASDAQ:DVLT) ("Datavault AI
PromiCell, Inc. presents during JP Morgan's 2026 Healthcare Conference9.1.2026 18:35:00 CET | Press release
MIAMI, FL / ACCESS Newswire / January 9, 2026 / PromiCell, Inc. (the "Company"), a clinical-stage cellular immunotherapy company uniquely positioned to advance potentially curative cell therapies for cancer patients, today announced that the Company's Chief Medical Officer, John Lee, MD, Ph.D., will present interim results of the Company's lead asset PRO CAR - 201A, a STEAP1 directed CAR T cell that is currently in the clinic as a first-in-human phase 1 trial for the treatment of metastatic castration-resistant prostate cancer (mCRPC), at Biotech Showcase 2026 in San Francisco, California on Monday, January 12, 2025 at 11:15 am PST at the Franciscan D (Ballroom Level). About PromiCell, Inc. PromiCell, is a clinical-stage cellular immunotherapy company with product candidates representing highly differentiated and novel CAR T and TCR T platforms to be developed across separate solid and hematologic types of cancer. Our pipeline of innovative products includes STEAP 1 CAR T cells, HA-1 T
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
